Phyllis C. Tien
Distinguished in Hepatitis C

Dr. Phyllis C. Tien

Infectious Disease
4150 Clement St, Infectious Diseases Section 111w, 
San Francisco, CA 
30 Years of Experience
Distinguished in Hepatitis C
4150 Clement St, Infectious Diseases Section 111w, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Phyllis Tien is an Infectious Disease provider in San Francisco, California. Dr. Tien has been practicing medicine for over 30 years and is rated as a Distinguished provider by MediFind in the treatment of Hepatitis C. Her top areas of expertise are HIV/AIDS, Hepatitis C, Menopause, and Hepatitis.

Her clinical research consists of co-authoring 300 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 43 articles in the study of Hepatitis C.

Specialties
Infectious Disease
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

4150 Clement St, Infectious Diseases Section 111w, San Francisco, CA 94121

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
Enrollment Status: Completed
Publish Date: July 28, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
Study Phase: Phase 4
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
View 2 Less Clinical Trials

300 Total Publications

Trajectories of BMI Before, During and Following the COVID-19 Pandemic among Participants in the MACS/WIHS Combined Cohort Study.
Trajectories of BMI Before, During and Following the COVID-19 Pandemic among Participants in the MACS/WIHS Combined Cohort Study.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: October 09, 2025
Similar Doctors
Distinguished in Hepatitis C
Dr. Andrew J. Desruisseau
Infectious Disease
Distinguished in Hepatitis C
Dr. Andrew J. Desruisseau
Infectious Disease

Regents Univ Of California Ucsf

505 Parnassus Ave, 
San Francisco, CA 
 (2.9 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Desruisseau is an Infectious Disease provider in San Francisco, California. Dr. Desruisseau is rated as an Advanced provider by MediFind in the treatment of Hepatitis C. His top areas of expertise are Hepatitis C, Hepatitis, Myelitis, and HIV/AIDS.

Distinguished in Hepatitis C
Dr. Anne F. Luetkemeyer
Infectious Disease
Distinguished in Hepatitis C
Dr. Anne F. Luetkemeyer
Infectious Disease

University Of California Sfgh Medical Group

1001 Potrero Ave, 
San Francisco, CA 
 (5.8 miles away)
Languages Spoken:
English
See accepted insurances

Anne Luetkemeyer is an Infectious Disease provider in San Francisco, California. Dr. Luetkemeyer is rated as an Advanced provider by MediFind in the treatment of Hepatitis C. Her top areas of expertise are HIV/AIDS, Hepatitis C, Hepatitis, and Syphilis.

Distinguished in Hepatitis C
Dr. Phillip S. Pang
Infectious Disease
Distinguished in Hepatitis C
Dr. Phillip S. Pang
Infectious Disease
300 Pasteur Dr, Mc 5107, 
Stanford, CA 
 (30.1 miles away)
650-723-6661
Languages Spoken:
English

Phillip Pang is an Infectious Disease provider in Stanford, California. Dr. Pang is rated as an Advanced provider by MediFind in the treatment of Hepatitis C. His top areas of expertise are Hepatitis C, Hepatitis, HIV/AIDS, and Hepatitis B.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tien's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile